pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
raps·Jul 16·1 min read
save

UK regulator reports rise in drug approvals and steps toward AI oversight in healthcare

Jul 16, 2026·read at raps ↗RegulatoryNeutral

The UK Medicines and Healthcare products Regulatory Agency (MHRA) released its 2025-2026 annual report to Parliament.

The agency highlighted that it approved more new medicines this year than in the previous year, marking an uptick in its approval activity.

It also reported the removal of a record number of illegal drugs from circulation during the period.

Additionally, the MHRA outlined plans to advance the regulation of artificial intelligence applications in healthcare.

source

This writeup was produced by pharmadog from original reporting by raps.

Original headline: “Recon: Lilly to buy psychedelic developer AtaiBeckley for up to $3.8B; FDA approves Merck’s novel cholesterol drug”

read at raps ↗
68 words · retrieved Jul 20
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LILLY
topics
Approval

related stories

  • Jun 16STAT+: Pharmalittle: We’re reading about Medicare and obesity drugs, Germany’s pricing plans, and moreSTAT
  • Jun 15STAT+: Lilly’s Ajax acquisition may have been worth itSTAT
  • Jun 9Gilead and Merck’s latest trial success and flopSTAT
  • Jun 4STAT+: Supreme Court backs generic drugmaker in ‘skinny labeling’ caseSTAT
  • Jun 4STAT+: Pharmalittle: We’re reading about fewer pharma investments in Germany, growing U.S. layoffs, and moreSTAT